FindTrial
Sign In

Perioperative high-dose dexamethasone regimen does not increase readmission rate in primary total joint arthroplasty: a retrospective large-scale study

Perioperative high-dose dexamethasone regimen does not increase readmission rate in primary total joint arthroplasty: a retrospective large-scale study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046445
Enrollment
Unknown
Registered
2021-05-15
Start date
2021-05-15
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage arthropathy

Interventions

control group:no dexamethasone
low-dose group:dexamethasone = 15mg

Sponsors

Sichuan University West China Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 94 Years

Inclusion criteria

Inclusion criteria: In our center patients undergoing primary joint replacement due to end-stage osteoarthritis, intravenous injection of dexamethasone with or without perioperative use.

Exclusion criteria

Exclusion criteria: 1. Use other glucocorticoids during the perioperative period; 2. Use glucocorticoids before surgery.

Design outcomes

Primary

MeasureTime frame
readmission rate;—

Countries

China

Contacts

Public ContactZhou Zongke

Sichuan University West China Hospital

zhouzongke@scu.edu.cn+86 18980601028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026